Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

PURPOSE: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cohen, Ezra E.W., Haraf, Daniel J., Kunnavakkam, Rangesh, Stenson, Kerstin M., Blair, Elizabeth A., Brockstein, Bruce, Lester, Eric P., Salama, Joseph K., Dekker, Allison, Williams, Rosalyn, Witt, Mary Ellyn, Grushko, Tatyana A., Dignam, James J., Lingen, Mark W., Olopade, Olufunmilayo I., Vokes, Everett E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903330/
https://ncbi.nlm.nih.gov/pubmed/20498391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.0397
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars